Professional Documents
Culture Documents
A
Consensus Report by the American Diabetes Association (ADA)
and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies, Vanita R. Aroda, Billy S. Collins, Robert A. Gabbay, Jennifer Green,
Nisa M. Maruthur, Sylvia E. Rosas, Stefano Del Prato, Chantal Mathieu, Geltrude Mingrone,
Peter Rossing, Tsvetalina Tankova, Apostolos Tsapas, and John B. Buse
CONSENSUS REPORT
The American Diabetes Association and the European Association for the Study
of Diabetes convened a panel to update the previous consensus statements on
the management of hyperglycemia in type 2 diabetes in adults, published since
2006 and last updated in 2019. The target audience is the full spectrum of the
professional health care team providing diabetes care in the U.S. and Europe. A 1
Leicester Diabetes Research Centre, University
systematic examination of publications since 2018 informed new recommenda- of Leicester, Leicester, U.K.
2
tions. These include additional focus on social determinants of health, the health Leicester National Institute for Health Research
care system, and physical activity behaviors, including sleep. There is a greater Biomedical Research Centre, University Hospitals
of Leicester NHS Trust, Leicester, U.K.
emphasis on weight management as part of the holistic approach to diabetes 3
Division of Endocrinology, Diabetes and
management. The results of cardiovascular and kidney outcomes trials involving Hypertension, Brigham and Women’s Hospital,
sodium–glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor Harvard Medical School, Boston, MA
4
National Heart, Lung, and Blood Institute,
agonists, including assessment of subgroups, inform broader recommendations
Bethesda, MD
for cardiorenal protection in people with diabetes at high risk of cardiorenal dis- 5
American Diabetes Association, Arlington, VA
6
ease. After a summary listing of consensus recommendations, practical tips for Duke Clinical Research Institute, Duke University
implementation are provided. School of Medicine, Durham, NC
7
Department of Medicine, Johns Hopkins University
School of Medicine, Baltimore, MD
8
Kidney and Hypertension Unit, Joslin Diabetes
Type 2 diabetes is a chronic complex disease, and management requires multifacto- Center, Harvard Medical School, Boston, MA
9
rial behavioral and pharmacological treatments to prevent or delay complications Department of Clinical and Experimental Medicine,
University of Pisa, Pisa, Italy
and maintain quality of life (Fig. 1). This includes management of blood glucose lev- 10
Clinical and Experimental Endocrinology, KU
els, weight, cardiovascular risk factors, comorbidities, and complications. This necessi- Leuven, Leuven, Belgium
11
tates that care be delivered in an organized and structured way, such as described in Universit
a Cattolica del Sacro Cuore, Rome, Italy
12
the chronic care model, and includes a person-centered approach to enhance en- Fondazione Policlinico Universitario A. Gemelli
gagement in self-care activities (1). Careful consideration of social determinants of IRCCS, Rome, Italy
13
Division of Diabetes and Nutritional Sciences,
health and the preferences of people living with diabetes must inform individualiza- School of Cardiovascular and Metabolic Medicine
tion of treatment goals and strategies (2). and Sciences, King’s College London, London, U.K.
14
This consensus report addresses the approaches to management of blood glucose Steno Diabetes Center Copenhagen, Herlev,
levels in nonpregnant adults with type 2 diabetes. The principles and approach for Denmark
15
Department of Clinical Medicine, University of
achieving this are summarized in Fig. 1. These recommendations are not generally Copenhagen, Copenhagen, Denmark
applicable to individuals with diabetes due to other causes, for example, monogenic 16
Department of Endocrinology, Medical University—
diabetes, secondary diabetes, and type 1 diabetes, or to children. Sofia, Sofia, Bulgaria
2754 Consensus Report Diabetes Care Volume 45, November 2022
DATA SOURCES, SEARCHES, AND stakeholder input, the recommendations of microvascular complications (11,12),
STUDY SELECTION presented herein reflect the values and and early intervention is essential (13).
The writing group members were ap- preferences of the consensus group. The greatest absolute risk reduction comes
pointed by the American Diabetes Associ- from improving very elevated glycemic lev-
ation (ADA) and European Association for THE RATIONALE, IMPORTANCE, els, and a more modest reduction results
the Study of Diabetes (EASD). The group AND CONTEXT OF GLUCOSE- from near normalization of plasma glucose
largely worked virtually, with regular tele- LOWERING TREATMENT levels (2,14). The impact of glucose control
conferences from September 2021, a Fundamental aspects of diabetes care in- on macrovascular complications is less
3-day workshop in January 2022, and a clude promoting healthy behaviors through certain but is supported by multiple meta-
face-to-face 2-day meeting in April 2022. medical nutrition therapy (MNT), physical analyses and epidemiological studies. Be-
The writing group accepted the 2012 (3), activity, and psychological support, as well cause the benefits of intensive glucose
2015 (4), 2018 (5), and 2019 (6) editions as weight management and tobacco/sub- control emerge slowly while the harms
of this consensus report as a starting stance abuse counseling as needed. This can be immediate, people with longer life
point. To identify newer evidence, a search is often delivered in the context of dia- expectancy have more to gain from early
17
Diabetes Centre, Clinical Research and Evidence- 05787-2) and Diabetes Care (https://doi.org/10.2337/ Committee on Clinical Affairs and approved by its
Based Medicine Unit, Aristotle University Thessaloniki, dci22-0034) by the European Association for the Study Executive Board. The article was reviewed for
Thessaloniki, Greece of Diabetes and American Diabetes Association. ADA by its Professional Practice Committee.
18
Harris Manchester College, University of Oxford,
A consensus report of a particular topic contains This article contains supplementary material online
Oxford, U.K.
19 a comprehensive examination and is authored by at https://doi.org/10.2337/figshare.20800537.
University of North Carolina School of Medicine,
an expert panel and represents the panel’s
Chapel Hill, NC © 2022 by the American Diabetes Association
collective analysis, evaluation and opinion. M.J.D.
Corresponding author: John B. Buse, jbuse@ and the European Association for the Study of
and J.B.B. were co-chairs for the Consensus
med.unc.edu Diabetes. Readers may use this article as long as
Report Writing Group. V.R.A., B.S.C., R.A.G., J.G.,
Received 2 August 2022 and accepted 4 August the work is properly cited, the use is educational
N.M.M., and S.E.R. were the writing group
2022 and not for profit, and the work is not altered.
members for ADA. S.D.P., C.M., G.M., P.R., T.T.,
More information is available at https://www.
This article is being simultaneously published in and A.T. were the writing group members for
diabetesjournals.org/journals/pages/license.
Diabetologia (https://doi.org/10.1007/s00125-022- EASD. The article was reviewed for EASD by its
diabetesjournals.org/care
Figure 1—Decision cycle for person-centered glycemic management in type 2 diabetes. Adapted from Davies et al. (5) with permission. BGM, blood glucose monitoring; BP, blood pressure; CGM, continuous
glucose monitoring; CKD, chronic kidney disease; CVD, atherosclerotic cardiovascular disease; DSMES, diabetes self-management education and support; HF, heart failure.
Davies and Associates
2755
how language matters. Language in dia- The best outcomes from DSMES are must be addressed to improve health out-
betes care should be neutral, free of achieved through programs with a theory- comes. Five social determinants of health
stigma, and based on facts; be strength- based and structured curriculum and with areas have been identified: socioeconomic
based (focus on what is working), respect- contact time of over 10 h (26). While on- status (education, income, and occupa-
ful, and inclusive; encourage collaboration; line programs may reinforce learning, a tion), living and working conditions, multi-
and be person-centered (18). People living comprehensive approach to education us- sector domains (e.g., housing, education,
with diabetes should not be referred to as ing multiple methods may be more effec- and criminal justice system), sociocultural
“diabetics” or described as “noncompliant” tive (26). Emerging evidence demonstrates context (e.g., shared cultural values, practi-
or blamed for their health condition. the benefits of telehealth or web-based ces, and experiences), and sociopolitical
DSMES programs (33), and these were context (e.g., societal and political norms
Diabetes Self-Management Education used with success during the coronavirus that are root-cause ideologies and policies
and Support disease 2019 (COVID-19) pandemic (34–36). underlying health disparities) (46). More
DSMES is a key intervention, as important Technologies such as mobile apps, simula- granularity on social determinants of health
to the treatment plan as the selection of tion tools, digital coaching, and digital self- as they pertain to diabetes is provided in
improve risk factors for cardiometabolic management (57). Additionally, time causes of therapeutic inertia are multi-
disease and quality of life (50). above and below range are useful varia- factorial, occurring at the levels of the
bles for the evaluation of treatment regi- practitioner, person with diabetes, and/
Glucose Management: Monitoring mens. Particular attention to minimizing or health care system (66). Interventions
Glycemic management is primarily as- the time below range in those with hypo- targeting therapeutic inertia have facili-
sessed with the HbA1c test, which was glycemia unawareness may convey bene- tated improvements in glycemic manage-
the measure used in trials demonstrating fit. If using the ambulatory glucose profile ment and timely insulin intensification
the benefits of glucose lowering (2,52). to assess glycemic management, a goal (67,68). For example, the involvement of
As with any laboratory test, HbA1c mea- parallel to an HbA1c level of <53 mmol/ multidisciplinary teams that include non-
surement has limitations (2,52). There mol (<7%) for many is time in range of physician providers with authorization
may be discrepancies between HbA1c re- >70%, with additional recommendations to prescribe (e.g., pharmacists, specialist
sults and an individual’s true mean blood to aim for time below range of <4% and nurses, and advanced practice providers)
glucose levels, particularly in certain ra- time at <3.0 mmol/L (<54 mg/dL) of may reduce therapeutic inertia (69,70).
cial and ethnic groups and in conditions <1% (2).
CV, cardiovascular; CVOT, cardiovascular outcomes trial; DKA, diabetic ketoacidosis; DKD, diabetic kidney disease; DPP-4, dipeptidyl peptidase 4; eGFR, estimated glomerular filtration rate; GI, gastroin-
testinal; GIP, gastric inhibitory polypeptide; GLP-1 RA, glucagon-like peptide 1 receptor agonist; HF, heart failure; NASH, nonalcoholic steatohepatitis; MACE, major adverse cardiovascular events; SGLT2,
sodium-glucose cotransporter 2; SQ, subcutaneous; T2DM, type 2 diabetes mellitus. *For agent-specific dosing recommendations, please refer to manufacturers’ prescribing information.
1
Tsapas et al. (223). 2Tsapas et al. (224).
Diabetes Care Volume 45, November 2022
maintained is important for weight loss lifestyle programs may be considered for Physical Activity Behaviors, Including
(5,6,22,72–74). glycemic benefit and can be adapted for Sleep
A network analysis comparing trials of specific cultural indications (83–87). Physical activity behaviors significantly
nine dietary approaches of >12 weeks’ du- The Diabetes Remission Clinical Trial impact cardiometabolic health in type 2
ration demonstrated reductions in HbA1c (DiRECT) demonstrated greater remis- diabetes (Fig. 2) (96–117). Regular aero-
from –9 to –5.1 mmol/mol (–0.82% to sion of diabetes with a weight manage- bic exercise (i.e., involving large muscle
–0.47%) with all approaches compared ment program than with usual best groups and rhythmic in nature) improves
with a control diet. Greater glycemic ben- practice care in adults with type 2 dia- glycemic management in adults with type 2
efits were seen with the Mediterranean diabetes, resulting in less daily time in hyper-
betes within 6 years of diagnosis. The
diet and low-carbohydrate diet (75). The glycemia and reductions of 7 mmol/mol
structured, primary care-led intensive
greater glycemic benefits of low-carbohy- (0.6%) in HbA1c (118), and induces clini-
weight management program involved to-
drate diets (<26% of energy) at 3 and cally significant benefits in cardiorespira-
tal diet replacement (3,452–3,569 kJ/day
6 months are not evident with longer tory fitness (101,110,119). These glycemic
[825–853 kcal/day] for 3–5 months) fol-
follow-up (72). In a systematic review of effects can be maximized by under-
lowed by stepped food reintroduction and
trials of >6 months’ duration, compared
insulin sensitivity and reduce energy intake (95% CI 34%, 53%) following metabolic Recent data have increased confidence
(117,125). However, “catch-up” weekend surgery in people with type 2 diabetes and in the safety of the SGLT2i drug class
sleep alone is not enough to reverse the a BMI <30 kg/m2 (136), significantly (141,142). Their use is associated with in-
impact of insufficient sleep (126). higher than that achieved with traditional creased risk for mycotic genital infections,
medical management (137). However, there which are reported to be typically mild
Weight Management Beyond is a strong association between duration of and treatable. While SGLT2i use can in-
Lifestyle Interventions diabetes and the likelihood of postoperative crease the risk of diabetic ketoacidosis
Medications for Weight Loss in Type 2 Diabetes diabetes remission. People with more re- (DKA), the incidence is low, with a modest
Weight loss medications are effective ad- cently diagnosed diabetes are more likely incremental absolute risk (142). The SGLT2i
juncts to lifestyle interventions and healthy to experience remission after metabolic cardiovascular outcome trials (CVOTs) have
behaviors for management of weight and surgery, and the likelihood of remission reported DKA rates of 0.1–0.6% compared
have also been found to improve glucose decreases significantly with duration of di- with rates of <0.1–0.3% with placebo
control in people with diabetes (127). abetes longer than about 5–8 years (138). (143–147), with very low rates in the HF
Newer therapies have demonstrated Even in people with diabetes who do not (148–151) and CKD (152,153) outcome
weight (5,6,164). Beyond improving HbA1c effects (164,168,169). Education should be efficacy or cardiorenal protection can be
in adults with type 2 diabetes, specific provided when initiating GLP-1 RA therapy. considered at treatment initiation to ex-
GLP-1 RA have also been approved for re- GLP-1 RA promote a sense of satiety, facili- tend the time to treatment failure (176).
ducing risk of MACE in adults with type 2 tating reduction in food intake. It is impor- Metformin should not be used in people
diabetes with established CVD (dulaglu- tant to help people distinguish between with an eGFR <30 ml/min per 1.73 m2,
tide, liraglutide, and subcutaneous sema- nausea, a negative sensation, and satiety, and dose reduction should be considered
glutide) or multiple cardiovascular risk a positive sensation that supports weight when the eGFR is <45 ml/min per 1.73 m2
factors (dulaglutide) (Table 1) and for loss. Mindful eating should be encouraged: (177). Metformin use may result in lower
chronic weight management (subcutane- eating slowly, stopping eating when full serum vitamin B12 concentrations and
ous liraglutide titrated to 3.0 mg once and not eating when not hungry. Smaller worsening of symptoms of neuropathy;
daily; subcutaneous semaglutide titrated meals or snacks, decreasing intake of therefore, periodic monitoring and supple-
to 2.4 mg once weekly). This is discussed high-fat and spicy foods, moderating al- mentation are generally recommended if
in the sections Medications for Weight cohol intake, and increasing water intake levels are deficient, particularly in those
Loss in Type 2 Diabetes and Personalized are also recommended. Slower or flexi- with anemia or neuropathy (178,179).
U.S. Food and Drug Administration (FDA) sulfonylureas in some observational stud- efficacy and safety are largely dependent
approved tirzepatide, a GIP and GLP-1 RA, ies have raised concerns, although find- on the education and support provided
for once-weekly subcutaneous administra- ings from systematic reviews have found to facilitate self-management (5,6). Care-
tion to improve glucose control in adults no increase in all-cause mortality rates ful consideration should be given to the
with type 2 diabetes as an addition to compared with other active treatments pharmacokinetic and pharmacodynamic
healthy eating and exercise. In the Phase (191). The incidence of cardiovascular profiles of the available insulins as well
III clinical trial program, tirzepatide dem- events was comparable in those treated as the matching of the dose and timing
onstrated superior glycemic efficacy to with a sulfonylurea or pioglitazone in the to an individual’s physiological require-
placebo (183,184), subcutaneous sema- Thiazolidinediones or Sulfonylureas and ments. Numerous formulations of insulin
glutide 1.0 mg weekly (185), insulin de- Cardiovascular Accidents Intervention Trial are available, with advances in therapy
gludec (186), and insulin glargine (187). (TOSCA.IT) (193), and no difference in the geared toward better mimicking physio-
For HbA1c, placebo-adjusted reductions incidence of MACE was found in people logical insulin release patterns. Chal-
of 21 mmol/mol (1.91%), 21 mmol/mol at high cardiovascular risk treated with gli- lenges of insulin therapy include weight
(1.93%), and 23 mmol/mol (2.11%) were mepiride or linagliptin (194), a medication gain, the need for education and titration
formulated as premixes, combining mix- is seen with subcutaneous semaglutide Liraglutide exhibited a lower risk than the
tures of the insulin with protamine sus- followed by the other GLP-1 RA and pooled effect of the other three medica-
pension and the rapid-acting insulin. SGLT2i, and the greatest reduction in tions on a composite cardiovascular out-
Analog-based mixtures may be timed in blood pressure is seen with the SGLT2i come comprising MACE, revascularization,
closer proximity to meals. Education on the and GLP-1 RA classes (224). As discussed or HF or unstable angina requiring hospi-
impact of dietary nutrients on glucose levels above, the novel GIP and GLP-1 RA tir- talization (245,246).
to reduce the risk of hypoglycemia while zepatide was associated with greater
using mixed insulin is important. Insulins glycemic and weight loss efficacy than PERSONALIZED APPROACH TO
with different routes of administration (in- semaglutide 1 mg weekly (185). TREATMENT BASED ON
haled, bolus-only insulin delivery patch INDIVIDUAL CHARACTERISTICS
pump) are also available (211–213). Combination Therapy AND COMORBIDITIES:
The underlying pathophysiology of type 2 RECOMMENDED PROCESS FOR
Combination GLP-1–Insulin Therapy. Two diabetes is complex, with multiple con- GLUCOSE-LOWERING
fixed-ratio combinations of GLP-1 RA with tributing abnormalities resulting in a natu- MEDICATION SELECTION
Figure 3—Use of glucose-lowering medications in the management of type 2 diabetes. ACEi, angiotensin-converting enzyme inhibitor; ACR, albumin/creatinine ratio; ARB, angiotensin receptor blocker; ASCVD,
atherosclerotic cardiovascular disease; CGM, continuous glucose monitoring; CKD, chronic kidney disease; CV, cardiovascular; CVD, cardiovascular disease; CVOT, cardiovascular outcomes trial; DPP-4i, dipep-
tidyl peptidase 4 inhibitor; eGFR, estimated glomerular filtration rate; GLP-1 RA, glucagon-like peptide 1 receptor agonist; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart
failure with reduced ejection fraction; HHF, hospitalization for heart failure; MACE, major adverse cardiovascular events; MI, myocardial infarction; SDOH, social determinants of health; SGLT2i, sodium-glucose co-
transporter 2 inhibitor; T2D, type 2 diabetes; TZD, thiazolidinedione.
Davies and Associates
2765
composite primary outcome of progres- diabetes and worsening HF, sotagliflozin in the overall population versus placebo
sion to renal replacement therapy, eGFR reduced the total number of cardiovascu- (142,249). Regarding GLP-1 RA, a meta-
of <15 ml/min per 1.73 m2, a doubling lar deaths or hospitalizations or urgent analysis of relevant CVOTs demonstrated
of serum creatinine level, or death from visits for HF compared with placebo re- the favorable effect of GLP-1 RA versus
cardiovascular or kidney causes. The Da- gardless of ejection fraction (150). All placebo on MACE and its individual com-
pagliflozin and Prevention of Adverse these data corroborate the salutary drug ponents, including stroke, HHF, and a
Outcomes in Chronic Kidney Disease class effects of SGLT2i on HF-related out- composite kidney outcome including se-
(DAPA-CKD) trial recruited participants comes in the setting of HF, irrespective of vere albuminuria (250,251). It should be
with and without type 2 diabetes with ejection fraction or diabetes status. noted, however, that the overall effect
an eGFR of 25–75 ml/min per 1.73 m2 Finally, among GLP-1 RA, the Effect of estimate for HHF seems to have been
and a urinary albumin/creatinine ratio Efpeglenatide on Cardiovascular Out- driven by CVOTs of albiglutide and efpe-
(UACR) of 20–500 mg/mmol [200–5,000 comes (AMPLITUDE-O) trial demonstrated glenatide, which are not available for
mg/g] (153). Results of the trial demon- a beneficial effect of weekly efpeglenatide clinical use. Similarly, the overall effect
strated a clear benefit of dapagliflozin on on MACE and on a composite kidney out- estimate for the composite kidney out-
implemented support the credibility of albumin excretion rate [UACR <3.0 mg/ and data on efficacy, safety, and outcome
the conclusions favoring use of SGLT2i or mmol (<30 mg/g)], moderate albuminuria benefits considering within-class heteroge-
GLP-1 RA in individuals with compelling [UACR 3.0–30 mg/mmol (30–300 mg/g)], neity. No CVOT is available that focuses
indications independent of the use of and severe albuminuria [UACR $30 mg/ on people with type 2 diabetes who are
metformin. mmol ($300 mg/g)]) (252). In addition, no at low cardiovascular risk. Some infer-
Similarly, other subgroup analyses have modification of the effect estimates for ences about the effect of glucose-lower-
explored the role of baseline cardiovascu- MACE, cardiovascular death or HHF, and ing medications as primary cardiovascular
lar risk as a potential effect modifier re- the composite kidney outcome was ob- prevention in populations with low car-
garding the effect of treatment on MACE, served for SGLT2i in subgroup meta- diovascular risk can be made from net-
HHF, or kidney outcomes. Consistency of analyses based on history of HF (142). work meta-analyses, suggesting that no
findings from between-trial and within- Regarding GLP-1 RA, a subgroup meta- agent or drug class has a notable benefi-
trial comparisons, formal statistical testing analysis found that their effect on MACE cial effect on cardiovascular events in low-
verifying the absence of a subgroup did not significantly differ between peo- risk individuals with diabetes (223,259).
effect, and the similarity of baseline ple with an eGFR <60 ml/min per 1.73
m2 and those with an eGFR $60 ml/min
population (266). Therefore, recommen- infarction, stroke, and lower extremity Sex Differences
dations for the selection of medications amputation over a 5-year period was In women with reproductive potential,
to improve cardiovascular and kidney most notable in people with diabetes the use of highly effective contraception
outcomes do not differ for older people. aged 18–44 years (275). Younger people should be ensured, such as long-acting re-
Older age should not be an obstacle to with type 2 diabetes should be consid- versible contraception (intrauterine device
treatment of individuals with established ered at very high risk for complications or progesterone implant), prior to pre-
or high risk for CVD. However, medica- and treated correspondingly. Early use scribing medications that may adversely
tion choices for people who are frail or of combination therapy may be consid- affect a fetus. Diabetes significantly in-
who have multiple comorbidities may re- ered, as the Vildagliptin Efficacy in Combi- creases the risk of cardiovascular compli-
quire modification for safety and tolera- nation with Metformin for Early Treatment cations in both sexes, and CVD causes
bility. People with diabetes should also of Type 2 Diabetes (VERIFY) trial findings most hospitalizations and deaths in
understand and be able to appropriately suggest that this approach provides supe- women and men with diabetes (280,281).
modify use of their prescribed medica- In the general population, women are at
rior and more durable effects on blood
tions during times of illness. Frailty is as- lower risk for cardiovascular events than
glucose levels than metformin monother-
to reduce NASH activity; pioglitazone sessions/week. Balance training ses- • In general, selection of medications to
therapy and metabolic surgery may also sions are particularly encouraged for improve cardiovascular and kidney out-
improve hepatic fibrosis (188,292–298). older individuals or those with limited comes should not differ for older people.
Although not licensed for this pur- mobility/poor physical function. • In younger people with diabetes
pose, it has therefore been suggested • Metabolic surgery should be consid- (<40 years), consider early combina-
that people with type 2 diabetes at in- ered as a treatment option in adults tion therapy.
termediate to high risk of fibrosis should with type 2 diabetes who are appro- • In women with reproductive potential,
be considered for treatment with piogli- priate surgical candidates with a BMI counseling regarding contraception and
tazone and/or a GLP-1 RA with evidence $40.0 kg/m2 (BMI $37.5 kg/m2 in taking care to avoid exposure to medi-
of benefit (291,299). Although SGLT2i people of Asian ancestry) or a BMI of cations that may adversely affect a fe-
therapy has also been shown to reduce 35.0–39.9 kg/m2 (32.5–37.4 kg/m2 in tus are important.
elevated levels of liver enzymes and he- people of Asian ancestry) who do not
patic fat content in people with NAFLD, achieve durable weight loss and im- PUTTING IT ALL TOGETHER:
at this time there is less evidence to provement in comorbidities (including hy- STRATEGIES FOR
Figure 4—Holistic person-centered approach to T2DM management. 1“Cardiovascular Disease and Risk Management” in Standards of Medical Care in Diabetes—2022 (141). ACEi, angiotensin-converting en-
zyme inhibitor; ARB, angiotensin receptor blockers; ASCVD, atherosclerotic cardiovascular disease; BP, blood pressure; CKD, chronic kidney disease; CV, cardiovascular; eGFR, estimated glomerular filtration
rate; GLP-1 RA, glucagon-like peptide 1 receptor agonist; HF, heart failure; SGLT2i, sodium-glucose cotransporter 2 inhibitor; T2D, type 2 diabetes.
Diabetes Care Volume 45, November 2022
care, comorbid conditions, degree of hy- approach to diabetes. Mental illness, in- Facilitating Healthy Behaviors and
perglycemia, risks of complications, and cluding depression, is associated with an Weight Management
susceptibility to medication side effects. increased risk of diabetes and with Promotion of healthy behaviors is central
Attention should be given to how the bal- poorer prognosis but may also compli- to the holistic management of type 2 di-
ance of risks and benefits of each inter- cate diabetes management and be a bar- abetes and should be addressed at the
vention is communicated to each person rier to self-management. time of diagnosis and throughout the
living with diabetes. Risk estimator tools, course of diabetes. Healthy behaviors in-
especially for CVD risk, may also be help- Practical Tips for Clinicians
clude healthy nutrition, regular physical
ful, but when using these tools one must • Consider each person living with dia- activity, adequate sleep, and smoking
be aware that they work best when they betes an individual with specific con- cessation. Health behaviors should al-
are derived from and/or are validated in text, risks, and preferences. ways be assessed and addressed when
a population similar to the population in • Health care systems should monitor glycemic targets are not met and when
which they are applied (307). These risk and address inequity in the delivery new pharmacotherapy or interventions
estimator tools are often developed in of evidence-based interventions for (e.g., metabolic surgery) are initiated.
loss, particularly GLP-1 RA with high symptoms, and treatment of hypogly- events are more likely to experience a
weight loss efficacy, should be considered, cemia when undertaking physical ac- benefit over intermediate time frames
as they can often provide 10–15% weight tivity or adopting a specific nutritional than those with cardiovascular risk factors
loss or more. Metabolic surgery, which is plan; prescribe glucagon in people at only. Through shared decision-making,
most effective when performed early dur- risk for severe hypoglycemia. considering an individual’s lifelong CVD
ing diabetes, can be considered in those • DSMES and MNT can help the person risk, introduction of a GLP-1 RA or SGLT2i
without a sufficient response to nonsurgi- living with diabetes to identify and ad- with proven cardiovascular benefit into
cal weight loss interventions based on dress barriers to implementing health- the regimen for a person with CVD risk
the specific context and preferences and ier behaviors. factors can be considered in the context
should be accompanied by health behav- See Supplementary Fig. 2. of increased treatment burden and po-
ior interventions. The benefits of meta- tential side effects with lower absolute
bolic surgery need to be balanced against Choice of Glucose-Lowering risk reduction.
its potential adverse effects, which vary Medication All individuals with diabetes and CKD
by procedure and include surgical compli- The choice of glucose-lowering agents (eGFR <60 ml/min per 1.73 m2 or UACR
>3.0 mg/mmol [>30 mg/g]) should re-
update (5,6), other classes of agents are agents with complementary mechanisms safety, and organ protection. While most
useful in combination with metformin or of action should be pursued. Tradition- people with diabetes require intensifica-
when metformin is contraindicated or ally, a stepwise approach was advocated, tion of glucose-lowering medications,
not tolerated. Selection of other glucose- in which a new agent is added to the ex- some require medication reduction or
lowering agents will be determined by isting regimen, but evidence is growing discontinuation, particularly if the ther-
the balance between the glucose-lowering to support a more proactive approach in apy is ineffective or associated with side
efficacy and the side effect profile of the many by combining glucose-lowering effects such as hypoglycemia or when
individual agents (see Table 1). agents from initial diagnosis (6). glycemic goals have changed because of
Special attention needs to be given to Early use of combinations of agents a change in clinical circumstances (e.g.,
populations in which hypoglycemia is most allows tighter glucose control than development of comorbidities or even
dangerous, for example, people with monotherapy with the individual agents, healthy ageing). Medication should be
frailty, in whom agents without risk of and thus combinations of agents are in- stopped, or the dose reduced, if there are
hypoglycemia need to be prioritized. If dicated in those who have HbA1c levels minimal benefits or if harm outweighs
sulfonylureas or insulin are used, consid- >16.3 mmol/mol (>1.5%) above their any benefit. Ceasing or reducing the dose
target at diagnosis (e.g., $70 mmol/mol
Figure 5—Place of insulin. *NPH insulin or preferably analog to reduce nocturnal hypoglycemia risk. 1More details can be found in Davies et al. (12)
and “Pharmacologic Approaches to Glycemic Treatment” in Standards of Medical Care in Diabetes—2022 (16). CGM, continuous glucose monitor-
ing; DSMES, diabetes self-management education and support; FPG, fasting plasma glucose; GLP-1 RA, glucagon-like peptide 1 receptor agonist;
SGLT2i, sodium-glucose cotransporter 2 inhibitor; T1D, type 1 diabetes; TIR, time in range.
and insulin is the best choice for the in- evidence supporting use of particular good efficacy and acceptable side effect
dividual, its introduction should not be agents in people with type 2 diabetes profiles, the initiation of insulin can be
delayed. When clinicians are not familiar with specific profiles (comorbidities, over- postponed in many to later stages of the
with insulin use, referral to specialist care weight/obesity) and with the availability disease. GLP-1 RA should be considered
is indicated. However, with the growing of multiple glucose-lowering agents with in all when no contraindications are
diabetesjournals.org/care Davies and Associates 2775
present before initiation of insulin ther- insulin requires increased DSMES and of overseeing the treatment of people
apy, as they allow lower glycemic targets self-monitoring of glucose levels and with type 2 diabetes. In particular, inter-
to be reached with a lower injection bur- adds complexity and cost to the ther- ventions using apps as tools to support
den and lower risk of hypoglycemia apy. In contrast to basal insulin analogs, DSMES have been shown to have an im-
and weight gain than with insulin the evidence supporting the choice of pact on outcomes (34).
alone. mealtime rapid-acting insulin analogs is For those needing insulin as part of
The preferred way of initiating insulin less clear (329). Another simpler and their treatment, smart insulin pens and
in people with type 2 diabetes is to add still popular way of combining mealtime insulin pumps (continuous subcutane-
basal insulin to the existing pharmaco- and basal insulin components is using ous insulin infusion [CSII]) are available.
logical therapy in conjunction with re- premixed insulins. Insulin analog-based Specific evidence on the benefit of
visiting health behaviors and rereferral combinations have the advantage of re- smart pens in people with type 2 diabe-
to DSMES. However, agents that cause sulting in fewer hypoglycemic events tes is still scarce. CSII use is associated
hypoglycemia in themselves, such as and weight gain than are typically ob- with small improvements in HbA1c and
sulfonylureas, should be discontinued served with human premixed insulin fewer hypoglycemic events, suggesting
to enhance postprandial blood glucose support physical activity, meal planning • Technology can be useful in people
levels and achieve HbA1c targets. Thera- and monitoring, medication-taking be- with type 2 diabetes but needs to be
peutic inertia in intensification of insulin havior, mindfulness, and stress manage- part of a holistic plan of care and sup-
therapy should be avoided, and, when ment. Evidence on the impact of these ported by DSMES.
clinicians are not familiar with multiple systems is variable and highly dependent • Consider CGM in people with type 2
daily injection therapy, referral to special- on the embedding of the technology in a diabetes on insulin.
ist care and/or DSMES is warranted. A more comprehensive approach. Evidence • Adapt the clinic/system to optimize ef-
straightforward way to introduce meal- for a beneficial impact of telehealth on fective use of technology among peo-
time insulin is to start with a short- or achieving treatment goals in those living ple with type 2 diabetes, particularly
rapid-acting insulin injection before the with type 2 diabetes is growing (333,334). to support behavior change through
meal associated with the largest glucose During the COVID-19 pandemic, tele- self-monitoring.
excursion. Adding mealtime rapid-acting health has proven to be an efficient way See Supplementary Fig. 3.
2776 Consensus Report Diabetes Care Volume 45, November 2022
Working Within the System to • Team-based care is required for inte- of care to disparate and unfavorable out-
Deliver Improved Care grated care of diabetes; this includes comes. Today, the major opportunities to
We are fortunate to have evidence on nu- coordination between multiple disci- improve diabetes outcomes in the near
merous effective interventions in type 2 plines (diabetes care and education term come from more effective imple-
diabetes, but translating this evidence into specialist, dietitians, psychologists, etc.) mentation of best evidence through orga-
practice cannot rest only with front-line and often other medical specialties (pri- nization of care at all levels (national to
clinicians during individual clinic visits. The mary care, endocrinology, ophthalmol- individual practices) and from addressing
systems of care that support front-line ogy, nephrology, etc.). social determinants of health. Every
clinicians have a significant role in improv- • Management of type 2 diabetes re- reader of this consensus report has a
ing diabetes clinical management, out- quires continuous quality improve- role to play in better implementation
comes, and experience for people living ment interventions tailored to the with a focus on equity. For providers,
with diabetes. Front-line clinicians must in- local setting. that could involve a focus on shared de-
form and drive the design of care, but the See Supplementary Fig. 3. cision-making to improve adherence to
systems of care should be held account- behavioral and medication interventions
that the right person is getting the right management are needed. The impact comprehensively assess the imple-
therapy at the right time while working of prioritizing early aggressive therapy mentation of recommendations and
to overcome barriers dependent on social to induce remission is unclear. create incentives for effective pro-
determinants of health is essential. Regu- • Cardiorenal protection. Data are re- grams. To optimally target resources,
latory reform, more efficient study con- quired to better inform when to select additional studies may be required on
duct and analysis, coordinated global a GLP-1 RA and/or an SGLT2i in the natural history and subpopulations,
efforts in defining outcomes and data col- setting of CVD but without HF or CKD as much of the rationale for screening
lection instruments, data sharing, explora- and to fully validate the recommenda- is based on studies conducted deca-
tion of new forms of health care delivery tion for combination therapy in those des ago.
(e.g., telehealth), and increased efforts to at high risk who do not meet glycemic • Technology. Remote care, wearables,
reach underserved populations, as were targets. As discussed, there is consider- apps, and decision support aids have
made to address COVID-19, would accel- able uncertainty about the absolute exploded in availability, and a clear
erate progress in defining and implement- benefits of GLP-1 RA and SGLT2i for rationale exists as to why they may
ing optimal approaches for diabetes care. CVD outcomes in those with risk fac- be of benefit. However, their optimal
interpretation of meta-analyses evaluating Sanofi, and Takeda. His employer receives re- Association and the European Association for the
the effects of glucose-lowering medications search funding from AstraZeneca and Boheringer Study of Diabetes. Diabetologia 2015;58:429–442
across subgroup populations and contributed Ingelheim. C.M. serves or has served on the advi- 5. Davies MJ, D’Alessio DA, Fradkin J, et al.
in applying GRADE guidance in the formulation sory panel for Novo Nordisk, Sanofi, MSD, Eli Lilly, Management of hyperglycaemia in type 2
of respective practice recommendations. D. Novartis, AstraZeneca, Boehringer Ingelheim, diabetes, 2018. A consensus report by the
Bradley (Ohio State University College of Medi- Roche, Medtronic, ActoBio Therapeutics, Pfizer, American Diabetes Association (ADA) and the
cine, Columbus, OH), P. Home (Newcastle Uni- Insulet, and Zealand Pharma. Financial compen- European Association for the Study of Diabetes
versity, Newcastle, U.K.), M.S. Kirkman sation for these activities has been received by (EASD). Diabetologia 2018;61:2461–2498
(University of North Carolina, Chapel Hill, NC), KU Leuven. KU Leuven has received research sup- 6. Buse JB, Wexler DJ, Tsapas A, et al. 2019
S. Dinneen (Galway University Hospitals, Gal- port for C.M. from Medtronic, Novo Nordisk, Sa- update to: Management of hyperglycaemia in
way, Ireland), H.W. Rodbard (Adventis Health- nofi, and ActoBio Therapeutics. C.M. serves or type 2 diabetes, 2018. A consensus report by the
Care Shady Grove Medical Center, Rockville, has served on the speaker’s bureau for Novo Nor- American Diabetes Association (ADA) and the
MD), G. Sesti (Sapienza University of Rome, disk, Sanofi, Eli Lilly, Boehringer Ingelheim, Astra- European Association for the Study of Diabetes
Rome, Italy), P. Newland-Jones (University of Zeneca, and Novartis. Financial compensation for (EASD). Diabetologia 2020;63:221–228
Southampton, Southampton, U.K.), E. Montanya these activities has been received by KU Leuven. 7. Schandelmaier S, Briel M, Varadhan R, et al.
(University of Barcelona, Barcelona, Spain), and G.M. is a consultant to Novo Nordisk, Fractyl, Re- Development of the instrument to assess the
M. Nauck (Medical Department I, St. Josef-Hospi- cor, Keyron, and Metadeq and is on the scientific credibility of effect modification analyses (ICEMAN)
18. Dickinson JK, Guzman SJ, Maryniuk MD, management education programmes: a narrative 46. Haire-Joshu D, Hill-Briggs F. The next
et al. The use of language in diabetes care and review and current innovations. Lancet Diabetes generation of diabetes translation: a path to health
education. Diabetes Care 2017;40:1790–1799 Endocrinol 2018;6:130–142 equity. Annu Rev Public Health 2019;40:391–410
19. Powers MA, Bardsley JK, Cypress M, et al. 31. Captieux M, Pearce G, Parke HL, et al. 47. Hill-Briggs F, Adler NE, Berkowitz SA, et al.
Diabetes self-management education and support Supported self-management for people with Social determinants of health and diabetes: a
in adults with type 2 diabetes: a consensus report type 2 diabetes: a meta-review of quantitative scientific review. Diabetes Care 2020;44:258–279
of the American Diabetes Association, the systematic reviews. BMJ Open 2018;8:e024262 48. Hill-Briggs F, Ephraim PL, Vrany EA, et al.
Association of Diabetes Care & Education 32. Lindekilde N, Scheuer SH, Rutters F, et al. Social determinants of health, race, and diabetes
Specialists, the Academy of Nutrition and Prevalence of type 2 diabetes in psychiatric population health improvement: Black/African
Dietetics, the American Academy of Family disorders: an umbrella review with meta-analysis Americans as a population exemplar. Curr Diab
Physicians, the American Academy of PAs, the of 245 observational studies from 32 systematic Rep 2022;22:117–128
American Association of Nurse Practitioners, reviews. Diabetologia 2022;65:440–456 49. Young-Hyman D, de Groot M, Hill-Briggs F,
and the American Pharmacists Association. 33. Dening J, Islam SMS, George E, Maddison R. Gonzalez JS, Hood K, Peyrot M. Psychosocial care
Diabetes Care 2020;43:1636–1649 Web-based interventions for dietary behavior in for people with diabetes: a position statement of
20. Davis J, Fischl AH, Beck J, et al. 2022 National adults with type 2 diabetes: systematic review of the American Diabetes Association. Diabetes
standards for diabetes self-management education randomized controlled trials. J Med Internet Res Care 2016;39:2126–2140
and support. Diabetes Care 2022;45:484–494 2020;22:e16437 50. Lingvay I, Sumithran P, Cohen RV, le Roux
systematic review and meta-analysis. Diabetes Obes type 2 diabetes mellitus. Eur J Epidemiol 2018;33: cluster-randomised trial. Lancet Diabetes
Metab 2018;20:1040–1043 157–170 Endocrinol 2019;7:344–355
62. Khunti K, Seidu S, Kunutsor S, Davies M. 76. Martınez-Gonzalez MA, Gea A, Ruiz-Canela 90. Look AHEAD Research Group. Does lifestyle
Association between adherence to pharmacotherapy M. The Mediterranean diet and cardiovascular intervention improve health of adults with
and outcomes in type 2 diabetes: a meta-analysis. health. Circ Res 2019;124:779–798 overweight/obesity and type 2 diabetes? Findings
Diabetes Care 2017;40:1588–1596 77. Estruch R, Ros E, Salas-Salvad o J, et al.; from the Look AHEAD randomized trial. Obesity
63. Polonsky WH, Henry RR. Poor medication PREDIMED Study Investigators. Primary prevention (Silver Spring) 2021;29:1246–1258
adherence in type 2 diabetes: recognizing the of cardiovascular disease with a Mediterranean 91. Houston DK, Neiberg RH, Miller ME, et al.
scope of the problem and its key contributors. diet supplemented with extra-virgin olive oil or Physical function following a long-term lifestyle
Patient Prefer Adherence 2016;10:1299–1307 nuts. N Engl J Med 2018;378:e34 intervention among middle aged and older adults
64. Konstantinou P, Kassianos AP, Georgiou G, 78. Papamichou D, Panagiotakos DB, Itsiopoulos with type 2 diabetes: the Look AHEAD study. J
et al. Barriers, facilitators, and interventions for C. Dietary patterns and management of type 2 Gerontol A Biol Sci Med Sci 2018;73:1552–1559
medication adherence across chronic conditions diabetes: a systematic review of randomised 92. Garvey WT. Long-term health benefits of
with the highest non-adherence rates: a scoping clinical trials. Nutr Metab Cardiovasc Dis 2019;29: intensive lifestyle intervention in the Look AHEAD
review with recommendations for intervention 531–543 study. Obesity (Silver Spring) 2021;29:1242–1243
development. Transl Behav Med 2020;10:1390– 79. Wang X, Li Q, Liu Y, Jiang H, Chen W. 93. Wing RR, Bolin P, Brancati FL, et al.; Look
1398 Intermittent fasting versus continuous energy- AHEAD Research Group. Cardiovascular effects of
or simple resistance activities. Diabetes Care 119. Najafipour F, Mobasseri M, Yavari A, et al. Diabetes Organizations. Diabetes Care 2016;39:
2016;39:964–972 Effect of regular exercise training on changes in 861–877
105. Rowlands A, Davies M, Dempsey P, Edwardson HbA1c, BMI and VO2max among patients with 133. Carmona MN, Santos-Sousa H, Lindeza L,
C, Razieh C, Yates T. Wrist-worn accelerometers: type 2 diabetes mellitus: an 8-year trial. BMJ et al.; CRI-O group. Comparative effectiveness of
recommending 1.0 mg as the minimum clinically Open Diabetes Res Care 2017;5:e000414 bariatric surgeries in patients with type 2 diabetes
important difference (MCID) in daily average 120. Borror A, Zieff G, Battaglini C, Stoner L. The mellitus and BMI $ 25 kg/m2: a systematic review
acceleration for inactive adults. Br J Sports Med effects of postprandial exercise on glucose control and network meta-analysis. Obes Surg 2021;31:
2021;55:814–815 in individuals with type 2 diabetes: a systematic 5312–5321
106. Yates T, Haffner SM, Schulte PJ, et al. review. Sports Med 2018;48:1479–1491 134. Currie AC, Askari A, Fangueiro A, Mahawar
Association between change in daily ambulatory 121. Guo S, Xu Y, Qin J, et al. Effect of tai chi on K. Network meta-analysis of metabolic surgery
activity and cardiovascular events in people with glycaemic control, lipid metabolism and body procedures for the treatment of obesity and
impaired glucose tolerance (NAVIGATOR trial): a composition in adults with type 2 diabetes: a diabetes. Obes Surg 2021;31:4528–4541
cohort analysis. Lancet 2014;383:1059–1066 meta-analysis and systematic review. J Rehabil 135. Cresci B, Cosentino C, Monami M, Mannucci
107. Saint-Maurice PF, Troiano RP, Bassett DR Jr, Med 2021;53:jrm00165 E. Metabolic surgery for the treatment of type 2
et al. Association of daily step count and step 122. Gupta U, Gupta Y, Jose D, et al. Effectiveness diabetes: a network meta-analysis of randomized
intensity with mortality among US adults. JAMA of yoga-based exercise program compared to controlled trials. Diabetes Obes Metab 2020;22:
2020;323:1151–1160 usual care, in improving HbA1c in individuals with 1378–1387
148. McMurray JJV, Solomon SD, Inzucchi SE, CREDENCE trial. Diabetes Obes Metab 2022;24: 177. Lalau JD, Kajbaf F, Bennis Y, Hurtel-Lemaire
et al.; DAPA-HF Trial Committees and Investigators. 1072–1083 AS, Belpaire F, De Broe ME. Metformin treatment
Dapagliflozin in patients with heart failure and 163. Heerspink HJL, Oshima M, Zhang H, et al. in patients with type 2 diabetes and chronic
reduced ejection fraction. N Engl J Med 2019; Canagliflozin and kidney-related adverse events kidney disease stages 3A, 3B, or 4. Diabetes Care
381:1995–2008 in type 2 diabetes and CKD: findings from the 2018;41:547–553
149. Packer M, Anker SD, Butler J, et al.; EMPEROR- randomized CREDENCE trial. Am J Kidney Dis 178. Out M, Kooy A, Lehert P, Schalkwijk CA,
Reduced Trial Investigators. Cardiovascular and renal 2022;79:244–256.e1 Stehouwer CDA. Long-term treatment with
outcomes with empagliflozin in heart failure. N Engl J 164. Nauck MA, Quast DR, Wefers J, Meier JJ. metformin in type 2 diabetes and methylmalonic
Med 2020;383:1413–1424 GLP-1 receptor agonists in the treatment of type 2 acid: post hoc analysis of a randomized controlled
150. Bhatt DL, Szarek M, Steg PG, et al.; diabetes–state-of-the-art. Mol Metab 2021;46: 4.3year trial. J Diabetes Complications 2018;32:
SOLOIST-WHF Trial Investigators. Sotagliflozin in 101102 171–178
patients with diabetes and recent worsening 165. Novo Nordisk. Prescribing information for 179. Aroda VR, Edelstein SL, Goldberg RB, et al.;
heart failure. N Engl J Med 2021;384:117–128 RYBELSUS. Plainsboro, NJ, Novo Nordisk, 2019. Diabetes Prevention Program Research Group.
151. Anker SD, Butler J, Filippatos G, et al.; Accessed 20 June 2022. Available from www. Long-term metformin use and vitamin B12
EMPEROR-Preserved Trial Investigators. Empagliflozin accessdata.fda.gov/drugsatfda_docs/label/2019/ deficiency in the Diabetes Prevention Program
in heart failure with a preserved ejection fraction. N 213051s000lbl.pdf Outcomes Study. J Clin Endocrinol Metab 2016;
Engl J Med 2021;385:1451–1461 166. Frias JP, Bonora E, Nevarez Ruiz L, et al. 101:1754–1761
189. Karagiannis T, Avgerinos I, Liakos A, et al. 202. Home PD, Pocock SJ, Beck-Nielsen H, et al.; 217. Linjawi S, Bode BW, Chaykin LB, et al. The
Management of type 2 diabetes with the dual GIP/ RECORD Study Team. Rosiglitazone evaluated for efficacy of IDegLira (insulin degludec/liraglutide
GLP-1 receptor agonist tirzepatide: a systematic cardiovascular outcomes in oral agent combination combination) in adults with type 2 diabetes
review and meta-analysis. Diabetologia 2022;65: therapy for type 2 diabetes (RECORD): a multicentre, inadequately controlled with a GLP-1 receptor
1251–1261 randomised, open-label trial. Lancet 2009;373:2125– agonist and oral therapy: DUAL III randomized
190. Sattar N, McGuire DK, Pavo I, et al. 2135 clinical trial. Diabetes Ther 2017;8:101–114
Tirzepatide cardiovascular event risk assessment: 203. Hanefeld M, Brunetti P, Schernthaner GH, 218. Aroda VR, Rosenstock J, Wysham C, et al.;
a pre-specified meta-analysis. Nat Med 2022;28: Matthews DR; QUARTET Study Group. One-year LixiLan-L Trial Investigators. Efficacy and safety of
591–598 glycemic control with a sulfonylurea plus LixiLan, a titratable fixed-ratio combination of
191. Khunti K, Chatterjee S, Gerstein HC, pioglitazone versus a sulfonylurea plus metformin insulin glargine plus lixisenatide in type 2
Zoungas S, Davies MJ. Do sulphonylureas still in patients with type 2 diabetes. Diabetes Care diabetes inadequately controlled on basal insulin
have a place in clinical practice? Lancet Diabetes 2004;27:141–147 and metformin: the LixiLan-L randomized trial.
Endocrinol 2018;6:821–832 204. Viscoli CM, Inzucchi SE, Young LH, et al.; IRIS Diabetes Care 2016;39:1972–1980
192. UK Prospective Diabetes Study (UKPDS) Trial Investigators. Pioglitazone and risk for bone 219. Lingvay I, Perez Manghi F, Garcıa-Hernandez
Group. Intensive blood-glucose control with fracture: safety data from a randomized clinical P, et al.; DUAL V Investigators. Effect of insulin
sulphonylureas or insulin compared with conventional trial. J Clin Endocrinol Metab 2017;102:914–922 glargine up-titration vs insulin degludec/liraglutide
treatment and risk of complications in patients with 205. Kahn SE, Zinman B, Lachin JM, et al.; on glycated hemoglobin levels in patients with
229. Li C, Luo J, Jiang M, Wang K. The efficacy 243. Wright AK, Carr MJ, Kontopantelis E, et al. 257. Lavalle-Cobo A, Masson W, Lobo M,
and safety of the combination therapy with GLP-1 Primary prevention of cardiovascular and heart Masson G, Molinero G. Glucagon-like peptide-1
receptor agonists and SGLT-2 inhibitors in type 2 failure events with SGLT2 inhibitors, GLP-1 receptor agonists and cardioprotective benefit in
diabetes mellitus: a systematic review and meta- receptor agonists, and their combination in type 2 patients with type 2 diabetes without baseline
analysis. Front Pharmacol 2022;13:838277 diabetes. Diabetes Care 2022;45:909–918 metformin: a systematic review and update
230. Guo M, Gu J, Teng F, et al. The efficacy and 244. Clegg LE, Penland RC, Bachina S, et al. Effects meta-analysis. High Blood Press Cardiovasc Prev
safety of combinations of SGLT2 inhibitors and of exenatide and open-label SGLT2 inhibitor 2021;28:605–612
GLP-1 receptor agonists in the treatment of type 2 treatment, given in parallel or sequentially, on 258. Husain M, Consoli A, De Remigis A, Pettersson
diabetes or obese adults: a systematic review and mortality and cardiovascular and renal outcomes Meyer AS, Rasmussen S, Bain S. Semaglutide reduces
meta-analysis. Endocrine 2020;67:294–304 in type 2 diabetes: insights from the EXSCEL trial. cardiovascular events regardless of metformin use: a
231. Eng C, Kramer CK, Zinman B, Retnakaran R. Cardiovasc Diabetol 2019;18:138 post hoc subgroup analysis of SUSTAIN 6 and
Glucagon-like peptide-1 receptor agonist and 245. Nathan DM. Glycemic outcomes in the PIONEER 6. Cardiovasc Diabetol 2022;21:64
basal insulin combination treatment for the glycemia reduction approaches in type 2 259. Palmer SC, Tendal B, Mustafa RA, et al.
management of type 2 diabetes: a systematic diabetes: a comparative effectiveness (GRADE) Sodium-glucose cotransporter protein-2 (SGLT-2)
review and meta-analysis. Lancet 2014;384: study. N Engl J Med. In press. inhibitors and glucagon-like peptide-1 (GLP-1)
2228–2234 246. Nathan DM. Glycemia reduction approaches receptor agonists for type 2 diabetes: systematic
232. Li D, Shi W, Wang T, Tang H. SGLT2 inhibitor in type 2 diabetes: a comparative effectiveness review and network meta-analysis of randomised
or recently diagnosed type 2 diabetes. Diabetes 283. Hu G, Jousilahti P, Qiao Q, Katoh S, 297. Russo MF, Lembo E, Mari A, et al. Insulin
Care 2018;41:1717–1725 Tuomilehto J. Sex differences in cardiovascular resistance is central to long-term reversal of
270. RISE Consortium. Lack of durable improve- and total mortality among diabetic and non- histologic nonalcoholic steatohepatitis after metabolic
ments in b-cell function following withdrawal of diabetic individuals with or without history of surgery. J Clin Endocrinol Metab 2021;106:750–761
pharmacological interventions in adults with myocardial infarction. Diabetologia 2005;48: 298. Hartman ML, Sanyal AJ, Loomba R, et al.
impaired glucose tolerance or recently diagnosed 856–861 Effects of novel dual GIP and GLP-1 receptor
type 2 diabetes. Diabetes Care 2019;42:1742–1751 284. Peters SAE, Huxley RR, Woodward M. agonist tirzepatide on biomarkers of nonalcoholic
271. Hannon TS, Arslanian SA. The changing face Diabetes as a risk factor for stroke in women steatohepatitis in patients with type 2 diabetes.
of diabetes in youth: lessons learned from compared with men: a systematic review and Diabetes Care 2020;43:1352–1355
studies of type 2 diabetes. Ann N Y Acad Sci meta-analysis of 64 cohorts, including 775,385 299. Ghosal S, Datta D, Sinha B. A meta-analysis
2015;1353:113–137 individuals and 12,539 strokes. Lancet 2014;383: of the effects of glucagon-like-peptide 1 receptor
272. TODAY Study Group. Effects of metformin, 1973–1980 agonist (GLP1-RA) in nonalcoholic fatty liver
metformin plus rosiglitazone, and metformin plus 285. Peters SAE, Huxley RR, Woodward M. disease (NAFLD) with type 2 diabetes (T2D). Sci
lifestyle on insulin sensitivity and b-cell function Diabetes as risk factor for incident coronary heart Rep 2021;11:22063
in TODAY. Diabetes Care 2013;36:1749–1757 disease in women compared with men: a 300. Coelho FDS, Borges-Canha M, von Hafe M,
273. Jalaludin MY, Deeb A, Zeitler P, et al. systematic review and meta-analysis of 64 et al. Effects of sodium-glucose co-transporter 2
Efficacy and safety of the addition of sitagliptin to cohorts including 858,507 individuals and 28,203 inhibitors on liver parameters and steatosis: a
evaluation_resources/guides/writing-smart- controlled type 2 diabetes using metformin and management of type 2 diabetes mellitus: sys-
objectives.htm sulfonylurea (VISUAL study): a randomized trial. tematic meta-review. J Med Internet Res 2021;
312. Pi-Sunyer X. The Look AHEAD trial: a review Diabetes Res Clin Pract 2015;109:141–148 23:e23252
and discussion of its outcomes. Curr Nutr Rep 324. Moses RG, Kalra S, Brook D, et al. A 335. Dicembrini I, Mannucci E, Monami M, Pala
2014;3:387–391 randomized controlled trial of the efficacy and L. Impact of technology on glycaemic control in
313. Cahn A, Raz I, Leiter LA, et al. Cardiovascular, safety of saxagliptin as add-on therapy in patients type 2 diabetes: A meta-analysis of randomized
renal, and metabolic outcomes of dapagliflozin with type 2 diabetes and inadequate glycaemic trials on continuous glucose monitoring and
versus placebo in a primary cardiovascular control on metformin plus a sulphonylurea. continuous subcutaneous insulin infusion. Diabetes
prevention cohort: analyses from DECLARE- Diabetes Obes Metab 2014;16:443–450 Obes Metab 2019;21:2619–2625
TIMI 58. Diabetes Care 2021;44:1159–1167 325. Moses RG, Round E, Shentu Y, et al. A 336. Evans M, Welsh Z, Ells S, Seibold A. The
314. Marso SP, Daniels GH, Brown-Frandsen K, randomized clinical trial evaluating the safety and impact of flash glucose monitoring on glycaemic
et al.; LEADER Steering Committee; LEADER Trial efficacy of sitagliptin added to the combination
control as measured by HbA1c: a meta-analysis
Investigators. Liraglutide and cardiovascular outcomes of sulfonylurea and metformin in patients with
of clinical trials and real-world observational
in type 2 diabetes. N Engl J Med 2016;375:311–322 type 2 diabetes mellitus and inadequate glycemic
studies. Diabetes Ther 2020;11:83–95
315. Gerstein HC, Colhoun HM, Dagenais GR, control. J Diabetes 2016;8:701–711
337. Martens T, Beck RW, Bailey R, et al.;
et al.; REWIND Investigators. Dulaglutide and 326. American Diabetes Association. Overcoming
MOBILE Study Group. Effect of continuous
cardiovascular outcomes in type 2 diabetes therapeutic inertia. Alexandria, VA, American
glucose monitoring on glycemic control in